Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | RAB9A | P51151 | 4/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1115813 | 0.89 | ACHE (0.38) | KMT2ASMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL687814 | 0.74 | EED (0.47) | KMT2ASMN1; SMN2RAB9ANPC1KDM4E | |
| SCHEMBL687468 | 0.73 | ALDH1A1 (0.44) | KMT2ASMN1; SMN2RAB9ANPC1KDM4E | |
| SCHEMBL669617 | 0.73 | APAF1 (0.41) | KMT2AKDM4ELMNAALDH1A1MEN1 | |
| Lithium SCHEMBL688043 | 0.73 | EED (0.46) | KMT2ASMN1; SMN2RAB9ANPC1KDM4E | |
| SCHEMBL688041 | 0.73 | EED (0.46) | KMT2ASMN1; SMN2RAB9ANPC1KDM4E | |
| SCHEMBL686641 | 0.72 | ALDH1A1 (0.42) | KMT2ASMN1; SMN2RAB9ANPC1KDM4E | |
| Lithium SCHEMBL686643 | 0.72 | ALDH1A1 (0.42) | KMT2ASMN1; SMN2RAB9ANPC1KDM4E | |
| SCHEMBL11620336 | 0.72 | APAF1 (0.44) | KMT2AKDM4ELMNAALDH1A1MEN1 | |
| SCHEMBL13814114 | 0.69 | CES1 (0.50) | KMT2ARAB9ANPC1PKMHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034939-B2 | 1-{3-H-imidazo[4,5-c]pyridin-2-yl}-3,4-dihydro-2H-pyrido[2,1-a] isoindole-6-one; anticarcinogenic agent: solid tumor and leukemia; neurodegenerative diseases: Alzheimer's and Huntington's diseases | AVENTIS PHARMA S.A.. (FR) | 2011-10-11 | — | — | US | disclosed |
| EP-1869042-B1 | NOVEL ISOINDOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME, PREPARATION THEREOF AND PHARMACEUTICAL USES THEREOF IN PARTICULAR AS INHIBITORS OF CHAPERONE PROTEIN HSP90 ACTIVITIES | AVENTIS PHARMA SA (FR) | 2011-02-02 | — | — | EP | disclosed |
| US-20080119507-A1 | Novel Isoindole Derivatives, Compositions Containing Same, Preparation Thereof and Pharmaceutical Uses Thereof in Particular as Inhibitors of Chaperone Protein HSP90 Activities | AVENTIS PHARMA S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
| EP-1869042-A2 | NOVEL ISOINDOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME, PREPARATION THEREOF AND PHARMACEUTICAL USES THEREOF IN PARTICULAR AS INHIBITORS OF CHAPERONE PROTEIN HSP90 ACTIVITIES | Aventis Pharma S.A. (FR) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006108948-A2 | NOVEL ISOINDOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME, PREPARATION THEREOF AND PHARMACEUTICAL USES THEREOF IN PARTICULAR AS INHIBITORS OF CHAPERONE PROTEIN HSP90 ACTIVITIES | AVENTIS PHARMA S.A. (FR) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119507-A1 | Novel Isoindole Derivatives, Compositions Containing Same, Preparation Thereof and Pharmaceutical Uses Thereof in Particular as Inhibitors of Chaperone Protein HSP90 Activities | HSP90B1, HSP90AB2P, HSP90AB1 | KMT2A 4714/4885SMN1; SMN2 3590/4885RAB9A 2175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.